Abstract Dolutegravir is a second-generation integrase strand transfer inhibitor (INSTI) currently under review by the US Food and Drug Administration for marketing approval. The in vitro, protein-adjusted 90 % inhibitory concentration (IC 90 ) of dolutegravir for wild-type virus is 0.064 lg/ml, and it retains in vitro anti-HIV 1 activity across a broad range of viral phenotypes that are known to confer resistance to the currently marketed INSTIs, raltegravir and elvitegravir. Dolutegravir has a terminal elimination half-life of 13-14 h and maintains concentrations over the in vitro, protein-adjusted IC 90 for more than 30 h following a single dose. Additionally, dolutegravir has low inter-subject variability compared with raltegravir and elvitegravir. A plasma exposure-response relationship has been well described, with antiviral activity strongly correlating with trough concentrations. Phase III trials have assessed the antiviral activity of dolutegravir compared with efavirenz and raltegravir in antiretroviral (ARV)-naive patients and found that dolutegravir achieved more rapid and sustained virologic suppression in both instances. Additionally, studies of dolutegravir activity in patients with known INSTI-resistant mutations have been favourable, indicating that dolutegravir retains activity in a variety of INSTI-resistant phenotypes. Much like currently marketed INSTIs, dolutegravir is very well tolerated. Because dolutegravir inhibits the renal transporter organic cation transporter 2, reduced tubular secretion of creatinine leads to non-progressive increases in serum creatinine.
Introduction
The well-tolerated integrase strand transfer inhibitors (INSTIs) are the newest class of antiretrovirals (ARVs), demonstrating potent anti-HIV activity through inhibition of the enzyme responsible for incorporating viral DNA into the host genome [1] . Two currently marketed INSTIs are raltegravir (MSD, Whitehouse Station, NJ, USA) and elvitegravir (Gilead Sciences, Foster City, CA, USA). Raltegravir was approved by the US Food and Drug Administration for marketing in 2007. Stribild (Gilead Sciences, Foster City, CA, USA), a combination tablet containing elvitegravir, was approved in 2012. Despite their comparatively short period of clinical use and a high genetic barrier to resistance, resistant phenotypes have been reported for both raltegravir and elvitegravir [2] [3] [4] [5] . Certain mutations, such as Q148H/R, N155H and Y143R confer cross-resistance between raltegravir and elvitegravir [5] , and further necessitate the development of secondgeneration INSTIs.
Dolutegravir, a novel INSTI currently under review by the FDA for marketing approval, is a chiral, non-racemic compound with a molecular weight of 419 g/mol (Fig. 1) . Dolutegravir fits loosely into the intasome binding pocket and retains its binding ability despite conformational changes in the pocket structure [6] . The ability to readjust its binding position is believed to enhance the genetic barrier to ARV resistance, consequently classifying dolutegravir as a second-generation INSTI.
Dolutegravir is highly potent, with an in vitro halfmaximal inhibitory concentration (IC 50 ) of 2.7 nM and an in vitro half-maximal effective concentration (EC 50 ) against HIV-1 of 0.51 nM in peripheral blood mononuclear cells [7] (raltegravir and elvitegravir have in vitro IC 50 values of 3.3 and 6 nM, respectively). Dolutegravir dissociates more slowly than raltegravir and elvitegravir from integrase-DNA complexes, with mean dissociation rate constant (k off ) [s -1 9 10 -6 ] values of 2.7, 22 and 71, respectively, for wild-type complexes, and 37, 1160 and 1130 for complexes expressing a single Q148H mutation [8] . Multiple in vitro studies utilizing a large variety of viral phenotypes no longer susceptible to raltegravir have demonstrated retained dolutegravir activity [7, 9, 10] . However, mutations at the 148 position of integrase did impart diminished in vitro dolutegravir susceptibility, with median in vitro IC 50 fold changes ranging from 3.01 to 27.12, compared with wild-type virus, depending on the type and number of secondary mutations [9, 10] . These preclinical findings suggested that dolutegravir would retain some antiviral activity in individuals previously exposed to raltegravir therapy.
Pharmacokinetics
The pharmacokinetic profile of dolutegravir, under singledose and steady-state conditions ranging from 2 to 100 mg per day, has been assessed in healthy and HIV-infected adults [11, 12] . Dolutegravir exhibits rapid absorption, with a median time to the maximum plasma concentration (t max ) ranging from 0.5 to 2 h. Dolutegravir also displays extensive protein binding, with [99 % of the dolutegravir blood plasma concentrations being bound to albumin and alpha 1-acid glycoprotein (AAG) [7, 13] . The terminal elimination half-life (t ) of dolutegravir was 13-14 h in healthy subjects and 11-12 h in HIV-infected subjects. Single doses of 5, 10, 25, 50 and 100 mg achieved plasma dolutegravir concentrations greater than the in vitro, proteinadjusted IC 90 of 0.064 lg/ml for more than 30 h following oral administration. Multiple daily doses ranging from 10 to 50 mg in both uninfected and infected subjects yielded trough plasma concentration (C trough ) values 3-25 times greater than this in vitro threshold (Table 1) [11, 12] . Dolutegravir exhibits lower inter-subject pharmacokinetic variability than other integrase inhibitors. Dolutegravir's coefficients of variation (CVs) are \30 % for both the area under the plasma concentration-time curve (AUC) and the maximum plasma concentration (C max ) in single-and multiple-dose studies, whereas raltegravir and elvitegravir demonstrate AUC CVs of 212 and 33-72 %, respectively [1, 14] .
Reese et al. [15] extensively characterized the metabolism and transport of dolutegravir, using in vitro model systems. Dolutegravir is primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT)-1A1 and is only a minor substrate for cytochrome P450 (CYP)-3A4. Dolutegravir inhibited CYP3A4 but not 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, or 2D6 in pooled human liver microsomes. Furthermore, at clinically relevant concentrations, neither inhibition nor induction of the aforementioned CYP enzymes or UGT1A1/2B7 is observed. Dolutegravir is a substrate for the transporters P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) but does not demonstrate inhibition or induction of the transporters Pgp, BCRP, organic anion transporter (OAT)-P1B1, OATP1B3, multidrug resistance protein (MRP)-2 or organic cation transporter (OCT)-1 at clinically relevant concentrations. Dolutegravir does potently inhibit the renal transporter OCT2 at concentrations below the peak concentrations demonstrated in clinical trials (in vitro IC 50 = 1.9 lM, dolutegravir C max = 7.97-14.7 lM).
While not believed to be clinically important, dolutegravir absorption is modestly affected by the fat content of a meal. Song et al. [16] observed increases of 133-242 % in the AUC from time zero to infinity (AUC ? ), C max and t max following a single 50 mg dose under fasted conditions compared with low-, moderate-and high-fat meals. Favourably, food decreases dolutegravir's inter-subject pharmacokinetic variability, with a median CV of 27.5 % for all pharmacokinetic parameters. Phase II and III investigations to date have not employed food restrictions for dolutegravir dosing [17] [18] [19] . As discussed below, those Fig. 1 Chemical structure of dolutegravir [57] clinical trials have demonstrated good dolutegravir efficacy and tolerability.
Although the pathways of dolutegravir's metabolism and transport may indicate that dolutegravir is relatively unaffected by population diversity, no studies have yet been conducted that specifically assessed the effects of demographic diversity on the pharmacokinetic parameters of dolutegravir. Further investigations evaluating the effect of sex and race on the pharmacokinetics of dolutegravir are warranted, as studies to date have primarily enrolled white men between the ages of 19 and 54 years with body mass index (BMI) values of 20.9-29.1 mg/m 2 [11] , leaving some portions of the HIV-infected population underrepresented.
Dolutegravir exposure has been studied in secondary body compartments including the central nervous system, female genital tract, male genital tract and colorectal tissue [20, 21] . Letendre et al. investigated the pharmacokinetics of dolutegravir in the cerebrospinal fluid (CSF) of 12 ARV-naive, HIV-infected subjects receiving 50 mg of dolutegravir daily with an abacavir/lamivudine backbone regimen [20] . Distribution to the CSF was similar to the unbound dolutegravir fraction in blood plasma at week 2 (mean CSF dolutegravir = 16.2 ng/ml, mean plasma unbound dolutegravir = 16.8 ng/ml) and at week 16 (mean CSF dolutegravir = 12.6 ng/ml, mean plasma unbound dolutegravir = 23 ng/ml). Additionally, dolutegravir exposure in the CSF for all subjects at week 16 ranged from 18-to 90-fold higher than the in vitro IC 50 for wild-type virus (0.2 ng/ml) [20] . These findings suggest free passage of the small molecule across the blood-brain barrier.
After single and multiple dosing, dolutegravir exposure in cervicovaginal fluid (CVF), cervical tissue and vaginal tissue was 5-7 % of blood plasma exposure. This is in contrast to raltegravir, which achieves *200 % of blood plasma exposure in CVF [22] . Despite this relatively low penetration, within 4-5 h after a single dose the CVF exposure is above the in vitro, protein-adjusted IC 90 . Similar to what has been previously identified for maraviroc [23] , since concentrations of the major drug-binding proteins (AAG and albumin) are less than 10 % of blood plasma concentrations in the CVF [24] , it may be that a larger proportion of this CVF concentration is available as protein-unbound (e.g. pharmacologically active) drug. In semen, dolutegravir concentrations are 6-7 % of blood plasma concentrations. This is strikingly different from raltegravir, which achieves seminal plasma concentrations that are 425-645 % of blood plasma concentrations [25, 26] . As with CVF, albumin concentrations in seminal plasma are less than 10 % of blood plasma concentrations [27] . Therefore, although not directly measured, it is possible that a larger proportion of the dolutegravir seminal plasma concentration is pharmacologically active [21] . Distribution to colorectal tissue was rapid and sustained, with 100 % of subjects achieving detectable dolutegravir concentrations within 1 h of a single dose, which remained above the in vitro, protein-adjusted IC 90 for the duration of the dosing interval [21] . Overall, dolutegravir exposure was *18 % of plasma concentrations.
Special Populations
Only a small proportion of the dolutegravir dose (\1 %) is excreted unchanged in the urine; therefore, dolutegravir is not expected to require dose adjustments in subjects with renal impairment [11] . The results of an open-label, singledose clinical trial evaluating the pharmacokinetic profile of dolutegravir in 16 subjects with normal or impaired renal function (creatinine clearance \30 ml/min) are currently being evaluated [28] . Initial reports have indicated that following a 50 mg single dose, the dolutegravir AUC ? and C max are reduced by 40 and 23 %, respectively, which is considered clinically insignificant [29] . One adverse event (dizziness) was reported in the renally impaired group, and AUC s area under the concentration-time curve during a dosing interval, C max maximum plasma concentration, C min minimum plasma concentration, C trough trough plasma concentration, CV % coefficient of variation expressed as a percentage, NA not available, t max time to maximum plasma concentration a Steady-state concentrations obtained from HIV-infected adults after ten doses of monotherapy with DTG tablets [12] b Steady-state concentrations obtained from healthy adults after ten doses of DTG suspension [11] two (nasal congestion and haemotoma) were reported in the healthy group. Currently, no dosage adjustments are recommended for dolutegravir in patients with renal impairment. Dolutegravir is extensively metabolized in the liver by UGT1A1 [11] . A preliminary study of a single 50 mg dolutegravir dose in a cohort of subjects with moderate hepatic impairment (Child-Pugh scores of 7-9) revealed that, overall, dolutegravir plasma exposure was unchanged and well tolerated in mild to moderate hepatic impairment [13] . However, it was noted that the unbound fraction of dolutegravir in plasma was higher in hepatically impaired subjects than in healthy volunteers (0.41 vs 0.23 %). Further investigation is warranted to assess the tolerability of multiple dolutegravir doses in patients with hepatic impairment. A large clinical trial evaluating the pharmacokinetic profile and immune response to dolutegravir in infants and adolescents 6 weeks-18 years of age is currently underway [30] . Preliminary steady-state pharmacokinetic data have been reported for 10 adolescent females with a mean age of 14 years (standard deviation [SD] 1.89) [31] . Following a weight-based, fixed dose of approximately 1 mg/kg, the dolutegravir AUC 24 and C trough were 46 mgÁh/ml (CV 43 %) and 0.9 mg/ml (CV 58 %), respectively. These fell within pre-defined target pharmacokinetic exposure ranges for both the AUC 24 (37-67 mgÁh/ml) and C trough (0.77-2.26 mg/ml). Furthermore, this exposure was similar to the exposure demonstrated in adult pharmacokinetic studies following a daily 50 mg dose (Table 1) . However, higher inter-subject variability was seen in adolescents than in adults. Dolutegravir and an optimized backbone regimen were well tolerated, with no adverse events leading to discontinuation of the study drug.
Pharmacodynamics
In 35 ARV-naive subjects, 10 days of monotherapy was investigated for dolutegravir doses of 2 mg, 10 mg and 50 mg daily. These doses resulted in a mean ± SD reduction in plasma HIV-1 RNA of -1.51 ± 0.58, -2.03 ± 0.49 and -2.46 ± 0.35 log 10 copies/ml, respectively ( Fig. 2) [12] . Dolutegravir doses of 10 and 50 mg once daily yielded C trough values that were *3 and 13 times higher than the in vitro, protein-adjusted IC 90 (0.064 lg/ml). Increased dolutegravir plasma exposure was correlated with reduced plasma HIV-1 RNA. Both loglinear and sigmoid maximum effect (E max ) models were evaluated to describe the pharmacokinetic-pharmacodynamic relationship of the compound. The exposureresponse relationship of dolutegravir was best described by a sigmoid E max model utilizing the following pharmacokinetic parameters: day 10 AUC from 0 to 24 hours (AUC 24 ), C max and the concentration at the end of the dosing interval (C s ), with E max fixed at -2.6 and the Hill factor fixed at 1 [32] . The in vivo EC 50 demonstrated by this E max model was 0.036 lg/ml. The model identified C trough as the pharmacokinetic parameter that best predicted the plasma viral load reduction on day 11 of monotherapy [12] . Additionally, the inhibitory quotient (IQ), calculated by C trough 7 protein-adjusted IC 90 , was also identified as a predictor of the virologic response. Based on these data, phase II studies have investigated daily doses of 10-50 mg.
The SPRING-1 (Phase IIb Study to Select a Once Daily Dose of GSK1349572 Administered with Either Abacavir/ Lamivudine or Tenofovir/Emtricitabine in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects) study [17] assessed daily dolutegravir 10 mg, 25 mg and 50 mg compared with the active control efavirenz 600 mg in ARV-naive subjects. All regimens contained a nucleoside reverse transcriptase inhibitor (NRTI) backbone of lamivudine plus abacavir or tenofovir disoproxil fumarate plus emtricitabine. Analysis at 48 weeks demonstrated more rapid and sustained virologic suppression, defined as HIV RNA \50 copies/ml, for all dolutegravir dosing arms compared with the efavirenz control group (Fig. 3 ) [17] . The proportion of subjects achieving virologic suppression in each dolutegravir dosing arm ranged from 90 to 96 % and from 88 to 91 % at 16 and 48 weeks, respectively. No significant difference in efficacy was observed among the dolutegravir dosing arms. Antiretroviral Therapy Naive Adult Subjects) study [19] , a phase III non-inferiority trial, assessed the efficacy of once-daily dolutegravir 50 mg against twice-daily raltegravir 400 mg as first-line treatment with dual-NRTI backbone therapy in ARV-naive subjects. Four hundred and eleven subjects were enrolled into each of the two blinded and masked treatment arms, and were followed for 48 weeks. The primary endpoint of SPRING-2 was the proportion of subjects achieving a viral load of \50 copies/ml at 48 weeks of therapy. The pre-specified noninferiority criterion was a lower 95 % confidence interval (CI) bound for the difference in the proportion of patients meeting the primary endpoints (dolutegravir minus raltegravir) of greater than -10 %. Dolutegravir was found to be non-inferior to raltegravir, with a difference of 2.5 % (95 % CI -2.2-7.1 %) [19] . Consistent with the findings from the SPRING-1 trial, dolutegravir demonstrated slightly more rapid and sustained virologic suppression when compared with raltegravir ( Fig. 3) . The more rapid rate of viral attenuation seen with dolutegravir may warrant consideration of this agent in clinical scenarios requiring rapid virologic suppression, such as HIVinfected patients presenting with AIDS-defining illness or women presenting late in pregnancy. Across most treatment arms, the proportion of virologic non-responders in the SPRING-1 and -2 trials was 0-3 % higher between the efavirenz and raltegravir-treated groups [17, 19] . No treatment-emergent INSTI resistance was identified among the dolutegravir treatment arms of SPRING-1 and -2.
The phase III, non-inferiority SINGLE (Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects) trial evaluated the efficacy of dolutegravir 50 mg once daily with an abacavir/lamivudine backbone regimen compared with efavirenz/tenofovir disoproxil fumarate/emtricitabine once daily in 833 subjects [33] . The dolutegravir arm demonstrated statistical superiority to efavirenz/tenofovir disoproxil fumarate/emtricitabine for the primary endpoint, with a difference in the proportion of subjects with HIV RNA \50 copies/ml at 48 weeks of ?7.4 % (95 % CI 2.5-12.3 %; p = 0.003) favouring the dolutegravir arm (Fig. 3) . Additionally, the median time to HIV RNA suppression in the dolutegravir group was -56 days compared with the median time in the efavirenz group (p \ 0.001). A subgroup analysis of the SPRING-2 and SINGLE studies investigated the efficacy of dolutegravir in subpopulations stratified by baseline viral load, CD4 count, sex, age and race. Dolutegravir demonstrated equivalent efficacy in all demographic subgroups for both phase III trials [34] .
To assess whether dolutegravir retained activity in the face of ARV resistance, the VIKING (Pilot Study to Assess the Antiviral Activity of GSK1349572 Containing Regimen in Antiretroviral Therapy (ART)-Experienced, HIV-1-Infected Adult Subjects with Raltegravir Resistance) study enrolled 51 subjects with documented INSTI resistance and Fig. 3 Efficacy results from phase II and III clinical trials: proportion of subjects with HIV \50 copies/ml in the SPRING-1, SPRING-2 [17, 19] , SINGLE [33] , VIKING [18] and VIKING-3 [35] trials at various weeks post-therapy initiation. BID twice daily, DTG dolutegravir, EFV efavirenz, FTC emtricitabine, OD once daily, RAL raltegravir, TDF tenofovir disoproxil fumarate resistance to at least one additional agent into two treatment cohorts [18] . The VIKING treatment plan consisted of adding dolutegravir to a failing backbone regimen for 10 days before optimizing the backbone regimen. Cohort I received dolutegravir 50 mg once daily and cohort II received 50 mg twice daily. A higher proportion of patients in cohort II met the definition of response at day 11 (HIV RNA C0.7 log 10 copies/ml decrease or \400 copies/ml) and at week 24 (HIV RNA \50 copies/ml) than in cohort I (Fig. 3) . Therefore, in the presence of INSTI resistance, a higher dose of dolutegravir may be warranted.
The single-arm VIKING-3 (Phase III Study to Demonstrate the Antiviral Activity and Safety of Dolutegravir in HIV-1 Infected Adult Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen) study [35] was designed to evaluate the efficacy of dolutegravir 50 mg twice daily in subjects with INSTI-resistant virus plus resistance to at least two other ARV classes. Dolutegravir was added to the failing backbone regimen for 8 days before the regimen was optimized. Interim analysis from VIKING-3 demonstrated that, despite high levels of ARV resistance, 63 % of the 72 evaluable subjects had viral loads of \50 copies/ml at 24 weeks [35] . These findings are consistent with preclinical work demonstrating the activity of dolutegravir against raltegravir-resistant virus. The VIKING studies provide encouraging data supporting the option of using dolutegravir 50 mg twice daily in salvage regimens.
In the first VIKING trial, treatment-emergent genotypic resistance was observed in four of 12 and in three of five subjects experiencing virologic failure in cohorts I and II, respectively [18] . All subjects experiencing treatmentemergent resistance also exhibited baseline INSTI-resistant mutations. In both cohorts, the presence of Q184H ? G140S with additional raltegravir-resistant mutations was associated with decreased virologic response to dolutegravir treatment. Similarly, subjects in the VIKING-3 trial with two or more primary mutations or a mutation of the Q148 pathway (Q148H/K/R) at baseline were more likely to experience virologic failure [35] . Only 69 % of subjects with Q148H/K/R and B1 secondary mutations and 48 % of those with Q148H/K/R and C2 secondary mutations met the definition of virologic response ([1 log HIV RNA decline or \50 copies/ml) at day 8.
The SAILING (Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered With an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase InhibitorNaive, Antiretroviral-Experienced Adults) study is an ongoing, phase III, non-inferiority investigation of the efficacy of 50 mg of dolutegravir once daily in ARVexperienced, INSTI-naive patients, compared with 400 mg raltegravir twice daily [36] . A 24-week interim analysis of the SAILING study demonstrated an adjusted difference in the proportion of subjects with viral loads \50 copies/ ml of ?9.7 % (95 % CI ?3.1 %, 15.9 %) in favour of the dolutegravir treatment group (p = 0.003). These preliminary findings further demonstrate that dolutegravir will likely be an effective option in ARV-experienced subjects.
Adverse Events
Dolutegravir has demonstrated a favourable safety profile in phase II and III trials. Dolutegravir was better tolerated than efavirenz, with only two adverse events (1 %) leading to subject withdrawal in the dolutegravir arm, compared with four (8 %) in the efavirenz arm of SPRING-1 [17] . Of the two adverse events leading to subject withdrawal from a dolutegravir dosing arm, only one (grade 2 dyspepsia) was deemed to be related to the study drug, while all four of the adverse events in the efavirenz arm were related to the study drug. Similarly, 10 subjects (2 %) in the SINGLE trial withdrew from the dolutegravir arm secondary to adverse events, compared with 42 (10 %) from the efavirenz arm [33] . Dolutegravir and raltegravir were similarly tolerated, with adverse event-related dropout rates of 2 % in each arm of the SPRING-2 trial [19] . Table 2 provides a summary of adverse events reported in SPRING-1, SPRING-2, SINGLE and VIKING. The majority of patients in each clinical trial experienced some adverse event during the course of treatment, with adverse event rates ranging from 57 to 89 %. Nausea, headache, diarrhoea and sleep disturbances were among the most commonly reported adverse events, being reported in 5-23 % of subjects. No dose-related patterns were identified for any type or frequency of adverse events reported in the dose-ranging SPRING-1 trial. The majority of treatment-emergent adverse events were mild or moderate in nature, with 5, 7 and 14 % of subjects in the dolutegravir treatment arms reporting any serious adverse events in SPRING-1, SPRING-2 and the first VIKING trial, respectively [17, 18] . Additionally, no serious study drugrelated adverse events were reported for the dolutegravir treatment arms of the SPRING-1 study or the VIKING trial. Three study drug-related serious adverse events (\1 %) were reported for the dolutegravir arm in SPRING-2: arrhythmia, hepatitis and hypersensitivity [19] . One hypersensitivity reaction (\1 %) was reported for the dolutegravir arm in the SINGLE trial [33] . In the efavirenz arm of the SPRING-1 and SINGLE trials, one subject (2 %) and eight subjects (2 %), respectively, reported study drug-related serious adverse events (one suicide attempt, four psychiatric adverse events, two hypersensitivity, one cerebral vascular accident and one renal failure) [17, 33] .
For the raltegravir arm of the SPRING-2 trial, five study drug-related serious adverse events (1 %) were reported (aphasia, convulsion, diarrhoea, hypersensitivity and increased creatine phosphokinase [CPK]) [19] .
The frequencies of graded laboratory abnormalities reported for SPRING-1, SPRING-2 and SINGLE were similar between all dolutegravir treatment and comparator arms. Laboratory abnormalities reported in 1-5 % of subjects included increased cholesterol, lipase, bilirubin, AST/ ALT, CPK and prothrombin time, as well as decreased phosphorous and neutrophil count [17, 19, 33] . Early investigation in SPRING-1, SPRING-2 and VIKING revealed a modest, non-progressive increase in serum creatinine associated with all dolutegravir dosing groups and cohorts, which was apparent after approximately 1 week of therapy and remained stable through 24 weeks [17] [18] [19] . Subsequent iohexol plasma clearance investigations revealed that the glomerular filtration rate (GFR) is not affected by dolutegravir [38] . Thus, this observation is likely due to dolutegravir-mediated inhibition of renal OCT2 transporter activity, with reduced tubular secretion of creatinine [15] . Dolutegravir use over 48 weeks of therapy does not appear to impact renal function [17, 19] although the long-term effects of dolutegravir on renal function are still unknown.
A supratherapeutic dose of dolutegravir (250 mg once) demonstrated maximal prolongation of the QT interval of 1.99 ms (90 % CI -0.55 to 4.53 ms) at 4 h post dose [39] .
Yet this change was not considered clinically relevant when compared with the QT prolongation of 9.58 ms (90 % CI 7.05-12.1) demonstrated by a single 400 mg dose of moxifloxacin as a positive control. Much like firstgeneration INSTIs, the side-effect profile of dolutegravir may make the compound a reasonable alternative in patients who are unable to tolerate the central nervous system or gastrointestinal side effects of efavirenz and protease inhibitors (PIs), respectively.
Drug-Drug Interactions
More than 20 drugs (Table 3) have been assessed for potential drug interactions with dolutegravir. These include ARVs likely to be used in combination therapy, such as NRTIs, non-nucleoside reverse transcriptase inhibitors (NNRTIs) and PIs. In addition, studies evaluating the drug interactions between dolutegravir and acidreducing agents, multivitamins (MVIs), oral hormonal contraceptives (OCs), antimycobacterial agents and direct-acting agents for hepatitis C virus (HCV), have been conducted.
CYP3A Probe Substrates
As previously discussed in this review, in vitro studies have demonstrated low potential for dolutegravir-mediated drug interactions by demonstrating that dolutegravir does not induce or inhibit CYP or UGT isoenzymes at clinically relevant concentrations [15] . To confirm these CYP3A findings in vivo, the drug interaction potential of dolutegravir was examined in a substudy of ten healthy volunteers receiving dolutegravir 25 mg daily for 10 days and a single dose of 3 mg oral midazolam syrup on day 10. The pharmacokinetic effect of dolutegravir on midazolam was compared with subjects receiving placebo with midazolam (n = 2). Plasma midazolam exposure was unchanged by dolutegravir (dolutegravir AUC = 15.4 ngÁh/ml vs placebo AUC = 16.3 ngÁh/ml), demonstrating that dolutegravir does not induce or inhibit CYP3A [11] . Thus, dolutegravirmediated drug interactions with CYP3A substrates are unlikely.
Nucleoside(tide) Reverse Transcriptase Inhibitors
Because NRTIs do not undergo hepatic transformation via the CYP metabolic pathway, drug interactions are not as common with this class compared with NNRTIs and PIs [40] . Thus, the drug interaction potential with NRTIs and dolutegravir is low. No clinical studies have quantified the interaction between dolutegravir and commonly used NRTIs such as emtricitabine, abacavir or lamivudine. However, as discussed previously, phase II/III clinical trials [19, 33] have successfully used dolutegravir in combination with these NRTIs without dose adjustments. Although the mechanistic drivers of tenofovir-mediated drug interactions are not well understood, tenofovir is known to reduce atazanavir exposure, possibly through induction of CYP or UGT metabolic pathways. For this reason, an open-label, repeat-dose study was conducted to assess the effects of concomitant dolutegravir and tenofovir disoproxil fumarate [41] . Fifteen healthy volunteers received 5 days of daily dolutegravir 50 mg, followed by a washout period of 6 days. Tenofovir disoproxil fumarate 300 mg daily was then administered for 7 days before daily dolutegravir 50 mg was added for an additional 5 days. The pharmacokinetic parameters of dolutegravir and tenofovir, assessed on the last day of each treatment period, demonstrated no clinically significant drug interaction [41] .
Non-Nucleoside Reverse Transcriptase Inhibitors
Efavirenz exhibits a complicated interaction profile. It is primarily a substrate of CYP2B6 and an inducer of UGT1A1, as well as a mixed inducer/inhibitor of CYP3A4 [40, 42] . Since efavirenz has the potential to induce both the major and minor metabolic pathways of dolutegravir, reduced dolutegravir plasma concentrations would be expected if these drugs were co-administered. The effects of efavirenz on the pharmacokinetics of dolutegravir have been evaluated in healthy subjects [43, 44] . A total of 12 volunteers received 50 mg of dolutegravir once daily for 5 days, then dolutegravir plus 600 mg of efavirenz once daily for 14 days. Co-administration with efavirenz reduced the dolutegravir AUC and C max by 57 and 39 %, respectively. However, the dolutegravir trough concentrations demonstrated a 75 % reduction, with a mean C trough of 0.22 lg/ml when dolutegravir was co-administered with efavirenz. Although C trough values remained above the in vitro, protein-adjusted IC 90 , they did fall below the in vivo concentration of the drug producing 90% of the maximum effect (EC 90 ) [0.324 lg/ml] calculated from the E max model discussed above [32, 43, 44] . Despite this reduction, the mean C trough was similar to C trough values in the 10 mg dolutegravir treatment arm of the SPRING-1 trial (0.3 lg/ml), which demonstrated efficacy similar to that of the 50 mg daily dosing arm [17] . Therefore, no dose adjustments are currently recommended when co-administering dolutegravir and efavirenz in INSTI-naive patients. However, careful clinical consideration should be given to individual patients. For those who may require more forgiveness for missed doses, or who may have increases in HIV RNA documented during careful virologic monitoring, use of dolutegravir 50 mg twice daily may be considered.
To investigate the drug interaction potential between the CYP3A substrate rilpivirine and dolutegravir, an openlabel, crossover study was conducted in 16 healthy subjects treated with dolutegravir 50 mg daily for 5 days, then rilpivirine 25 mg daily for 11 days, followed by combination treatment with dolutegravir and rilpivirine for 5 days [45] . Consistent with in vitro findings, co-administration did not significantly impact dolutegravir plasma exposure, with only slight increases of 10-18 % in the AUC, C max and C trough . Similarly, rilpivirine plasma exposure was not significantly altered by the presence of dolutegravir (the AUC, C max and C trough increased by 6-18 %).
Due to its ability to induce CYP isoenzymes and UGT1A1 [46] , etravirine, a second-generation NNRTI, has the potential to reduce dolutegravir plasma concentrations. Song et al. conducted two open-label, crossover studies to evaluate the effects of etravirine alone or in combination with ritonavir-boosted PIs on the pharmacokinetics of dolutegravir in healthy subjects. In the first study, 15 subjects received 50 mg of dolutegravir daily for 5 days, followed by dolutegravir in combination with 200 mg of etravirine twice daily for 14 days. In the second study, 16 subjects received 50 mg of dolutegravir daily for 5 days, followed by 14 days of dolutegravir in combination with etravirine 200 mg plus lopinavir/ritonavir 400/100 mg twice daily (n = 8) or darunavir/ritonavir 600/100 mg twice daily (n = 9). Pharmacokinetic samples were collected on the last day (day 5 and day 14) of each dosing period [47] .
Co-administration of etravirine alone led to a 50-88 % reduction in the dolutegravir AUC, C max and C trough . Yet combining etravirine with boosted PIs attenuated this interaction. It was shown that etravirine combined with lopinavir/ritonavir slightly increased the dolutegravir AUC, C max and C trough by 7-26 %, while etravirine combined with darunavir/ritonavir only reduced the dolutegravir AUC, C max and C trough by 12-37 %. Dolutegravir plasma exposure remained [9-fold above the in vitro, proteinadjusted IC 90 for the duration of the dosing interval. The authors concluded that while dolutegravir should not be administered in an etravirine-containing regimen alone, this combination might be considered without dose adjustments in a regimen containing lopinavir/ritonavir or darunavir/ritonavir [47] .
Protease Inhibitors
UGT1A1 inhibitors, such as atazanavir, have the potential to increase dolutegravir plasma concentrations. Conversely, ritonavir is a well-known inducer of the UGT1A1 pathway and thus has the potential to decrease dolutegravir plasma concentrations. A randomized, open-label, crossover study was conducted to assess the effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of dolutegravir [48] . Twenty-four healthy volunteers received dolutegravir 30 mg daily for 5 days, followed by co-administration of dolutegravir and atazanavir 400 mg daily or atazanavir/ritonavir 300/100 mg daily for 14 days. Giving atazanavir alone increased plasma dolutegravir exposure by 50-180 %, whereas giving atazanavir/ ritonavir increased dolutegravir exposure by only 34-121 %. This diminished effect is likely related to ritonavirmediated UGT1A1 induction, with ritonavir attenuating the inhibitory effect of atazanavir on this pathway. Co-administration of both atazanavir and atazanavir/ritonavir with dolutegravir did produce modest increases in dolutegravir exposure. Yet no increase in adverse effects was seen, and the mean AUC values (87.4 lg ml -1 h) were still lower than those achieved by a well-tolerated single dose of dolutegravir 100 mg in phase I studies (131 lg ml -1 h) [11] . Thus, despite a modest increase in dolutegravir exposure, it was determined that no dose adjustment for dolutegravir is necessary when it is co-administered with atazanavir or atazanavir/ritonavir [48] .
Darunavir and lopinavir are well-known inhibitors of the CYP3A4 pathway and therefore may increase dolutegravir plasma concentrations. In a randomized, open-label, crossover study, 30 subjects received 30 mg of dolutegravir once daily for 5 days and were then randomized to receive dolutegravir with lopinavir/ritonavir 400/100 mg twice daily or darunavir/ritonavir 600/100 mg twice daily for 14 days. Lopinavir/ritonavir did not significantly affect dolutegravir exposure, whereas darunavir/ritonavir decreased dolutegravir exposure by 11-38 % [49] . However, this reduction was not deemed clinically significant, as the dolutegravir C trough was still *7-fold higher than the in vitro, protein-adjusted IC 90 despite use of a lower dose (30 mg) of dolutegravir than was assessed in phase II/III trials.
Tipranavir exhibits a complicated drug interaction profile, as it is both a substrate and an inducer of CYP3A4, the minor metabolic pathway for dolutegravir [50] . The interaction potential between dolutegravir and tipranavir/ritonavir was investigated in an open-label, single-sequence study. Eighteen healthy volunteers received 50 mg of dolutegravir once daily for 5 days, then 7 days of 500/200 mg of tipranavir/ritonavir twice daily alone, followed by dolutegravir plus tipranavir/ritonavir combined for 5 days [43, 44] . Co-administration of tipranavir/ritonavir lowered dolutegravir pharmacokinetic parameters (the AUC, C max and C trough ) by 59, 46 and 76 %, respectively. However, dolutegravir concentrations remained well above the in vitro, protein-adjusted IC 90 and still achieved C trough values equivalent to the C trough demonstrated by daily dolutegravir 10 mg in the phase II dose-ranging trial (0.29 vs 0.3 lg/ml). Consequently, it was concluded that dose adjustments are not necessary for dolutegravir when it is combined with tipranavir/ritonavir in INSTI-naive patients [43, 44] .
The effect of concomitant fosamprenavir/ritonavir on the pharmacokinetic profile of dolutegravir has also been evaluated. In 12 healthy adult subjects, fosamprenavir/ ritonavir was shown to decrease the dolutegravir AUC, C max and C trough by 24-50 % [51] . Since dolutegravir exposure at the end of the dosing interval remained 4-fold greater than the in vitro, protein-adjusted IC 90 ; this decrease in exposure was deemed clinically insignificant, and standard dolutegravir dosing may be used when fosamprenavir/ritonavir is combined with dolutegravir.
Acid-Reducing Agents
All INSTI activity is dependent on binding to magnesium ions located at the catalytic site of the integrase enzyme to inhibit transfer of the viral DNA strand into the host genome. Therefore, chelation with therapeutic agents containing metal cations can occur. An open-label, randomized, crossover study evaluating the effect of co-administration of dolutegravir with metal cation-containing products, such as antacids and MVIs, was performed [52] . Sixteen subjects received 50 mg of dolutegravir alone, together with a single oral dose of a One A Day Maximum MVI (Bayer Corporation, Morristown NY, USA), with a single oral dose of Maalox Advances Maximum Strength Liquid antacid (Novartis, Parsippany NJ, USA), and 2 h before a single dose of antacid. Expectedly, concurrent administration of the MVI resulted in a modest (33 %) reduction in the dolutegravir AUC. Concomitant and staggered antacid administration reduced single-dose dolutegravir exposure by 74 and 26 %, respectively. While concomitant administration of MVI and staggered administration of antacids did produce a modest reduction in the dolutegravir AUC and C trough values, in both treatment groups the C trough was still 5-to 6-fold greater than the in vitro, proteinadjusted IC 90 . Therefore, it was recommended that dolutegravir should be administered at least 2 h before, or 6 h after, an antacid, and may be given concomitantly with a MVI [52] .
An interaction between dolutegravir and proton pump inhibitors (PPIs) might occur either through a change in absorption-limiting solubility caused by altering gastric pH or through a metabolic interaction via CYP isoenzymes. To evaluate the effect of pH-altering agents on dolutegravir exposure, 12 healthy subjects received a single 50 mg dose of dolutegravir under fasted conditions, followed by omeprazole 40 mg once daily for 5 days as part of a randomized, open-label, crossover study. On day 5, subjects also received a single 50 mg dose of dolutegravir 2 h after omeprazole administration [52] . Simultaneous administration of omeprazole resulted in a non-significant reduction in dolutegravir exposure, with the geometric least squares mean (GLSM) ratios of the AUC, C max and C 24 ranging from 0.92 to 1.00. Since co-administration of omeprazole minimally affected dolutegravir plasma exposure, dolutegravir may provide a clinical alternative to once-daily PI-containing regimens (specifically atazanavir/ritonavir) in patients requiring acid-controlling pharmacotherapy [52] .
Antimycobacterial Agents
Rifamycins are commonly used in the treatment of tuberculosis (TB) and present a challenge in HIV/TB co-infection due to complicated drug interaction profiles. Rifampin is a potent CYP and UGT pathway inducer, and rifabutin, a CYP3A4 substrate, requires bidirectional dose adjustments when used with some CYP3A4 inhibitors. To assess the pharmacokinetic drug interaction potential of rifamycins with dolutegravir, Dooley et al. [53] conducted an openlabel, fixed-sequence, crossover study. Eleven healthy subjects in arm 1 received 50 mg of dolutegravir once daily for 7 days, followed by 50 mg of dolutegravir twice daily for 7 days, and then 50 mg of dolutegravir twice daily co-administered with 600 mg of rifampin once daily for 14 days. Nine healthy subjects in arm 2 received 50 mg of dolutegravir once daily for 7 days, followed by 50 mg of dolutegravir once daily together with 300 mg of rifabutin once daily for 14 days. Pharmacokinetic comparison in arm 1 demonstrated that 50 mg of dolutegravir twice daily administered with rifampin 600 mg daily resulted in only modestly increased plasma dolutegravir exposure when compared with 50 mg of dolutegravir once daily alone (mean AUC = 33 % increase, C trough = 22 % increase). This indicates that dolutegravir dosing should be increased to 50 mg twice daily when it is combined with the inducer rifampin. Comparison in arm 2 showed that co-administration of dolutegravir 50 mg daily and rifabutin 300 mg daily resulted in a modest (30 %) decrease in the dolutegravir C trough , which was still 8-fold greater than the in vitro, protein-adjusted IC 90 . Therefore, rifabutin may provide a better clinical option for the treatment of TB in patients on a dolutegravir-containing regimen, as no dolutegravir dose adjustments are required [53] .
Oral Contraceptives
Although the potential for a drug interaction between dolutegravir and OCs is low, a double-blind, crossover study was designed to evaluate potential drug interactions. Sixteen healthy females were randomized to receive oncedaily Ortho-Cyclen, containing norgestimate (NGMN) and ethinyl estradiol (EE) from day 1 to day 21 of their menstrual cycle, plus either 50 mg of dolutegravir twice daily or placebo twice daily for 10 days. The subjects then switched to the alternate treatment for another 10 days [54] . Expectedly, the pharmacokinetic parameters of dolutegravir were not altered in the presence of NGMN or EE when dolutegravir was compared with historical controls. Plasma hormonal pharmacokinetic profiles were also unchanged by the presence of dolutegravir, as evidenced by GLSM ratios of 1.03 and 0.975 for EE and NGMN, respectively. Additionally, administering dolutegravir with Ortho-Cyclen had no effect on any pharmacodynamic marker of OC activity (e.g. luteinizing hormone, follicle stimulating hormone and progesterone levels) [54] .
Hepatitis Agents
Boceprevir and telaprevir are HCV PIs prescribed in combination with pegylated interferon and ribavirin for the treatment of HCV. Both boceprevir and telaprevir have demonstrated strong inhibition of CYP3A4/5 metabolic pathways and thus have the potential to increase plasma dolutegravir exposure through inhibition of its minor metabolic pathway. An open-label, two-cohort study in healthy adult subjects was conducted to assess the pharmacokinetics of dolutegravir in the presence of boceprevir and telaprevir [55] . Twenty-eight subjects received dolutegravir 50 mg once daily for 5 days and were then randomized to receive dolutegravir in combination with either boceprevir 800 mg three times daily or telaprevir 750 mg three times daily for 10 days. Co-administration of boceprevir and dolutegravir increased the dolutegravir C trough by 8 % but had no effect on the AUC or C max . Co-administration of telaprevir and dolutegravir resulted in increased dolutegravir plasma exposures relative to dolutegravir alone, as evidenced by 25, 19 , and 37 % increases in the AUC, C max and C trough , respectively. Hence, it was concluded that dolutegravir could be co-administered without dose adjustment in HIV/ HCV co-infected patients receiving HCV treatment with boceprevir and telaprevir [55] .
Opioid Agonists
Methadone is a racemic opioid receptor agonist commonly used for management of chronic pain or opioid addiction. Methadone is extensively metabolized by the CYP pathway and interacts with a number of different therapeutic agents. An open-label, crossover study evaluated the effects of dolutegravir co-administered with methadone in 12 opioid-dependent subjects receiving individualized doses of daily methadone [54] . Plasma exposure of both R-and S-methadone was not significantly altered by dolutegravir, with GLSM ratios for the AUC, C max and C trough ranging from 0.95 to 1.03. Because the study subjects were on stable methadone therapy prior to enrolment, this study was unable to assess the effects of methadone on the pharmacokinetic parameters of dolutegravir. A previous in vitro study has found that methadone only modestly induces UGT1A1 in hepatic microsomes at concentrations higher (10-50 lM) than the mean peak concentrations of methadone treatment demonstrated by Song et al.
(1.36 lM) [54, 56] . Considering that UGT1A1 is the primary metabolic pathway of dolutegravir, a methadonemediated drug interaction would be unexpected.
Conclusions
Dolutegravir is a second-generation INSTI that preferentially blocks the strand transfer step during the viral integration process. The favourable and predicable pharmacokinetic profile of dolutegravir offers several clinical advantages over currently marketed INSTIs. The lack of an effect on drug transporters and CYP enzymes is of value for an HIV-infected population requiring poly-pharmacy. Additionally, the drug exposure achieved by once-daily dolutegravir dosing negates the need for a concomitant pharmacokinetic enhancing agent (such as ritonavir or cobicistat), which also minimizes the drug interaction potential. Dolutegravir also has a favourable safety profile, with nausea, headache and diarrhoea being seen in\20 % of patients. Dolutegravir has potent antiretroviral activity in both ARVnaive and ARV-experienced patients, including those with first-generation INSTI resistance mutations.
With its potent activity, tolerability, ease of dosing and minimal drug interaction profile, dolutegravir is poised to become one of the key components in the treatment of HIV infection.
